scispace - formally typeset
J

Joann Belden

Researcher at Indiana University

Publications -  9
Citations -  1326

Joann Belden is an academic researcher from Indiana University. The author has contributed to research in topics: Placebo & Randomized controlled trial. The author has an hindex of 9, co-authored 9 publications receiving 1266 citations. Previous affiliations of Joann Belden include Indiana University – Purdue University Indianapolis.

Papers
More filters
Journal ArticleDOI

A controlled trial of rasagiline in early Parkinson disease: The tempo study

Andrew Siderowf, +89 more
- 01 Dec 2002 - 
TL;DR: Rasagiline is effective as monotherapy for patients with early PD and the 2 dosages in this trial were both effective relative to placebo.
Journal ArticleDOI

Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease

Tatiana Foroud, +98 more
- 11 Mar 2003 - 
TL;DR: Mutations in the parkin gene occur among individuals with PD with an older age at onset (≥60 years) who have a positive family history of the disease, and the clinical findings of parkin-positive individuals are remarkably similar to those without mutations.
Journal ArticleDOI

A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease

Karl Kieburtz, +123 more
- 02 Jan 2007 - 
TL;DR: Coenzyme Q10 and GPI-1485 may warrant further study in Parkinson disease, although the data are inconsistent, and additional factors should be considered in the selection of agents for Phase III studies.
Journal ArticleDOI

Significant Linkage of Parkinson Disease to Chromosome 2q36-37

Nathan Pankratz, +99 more
TL;DR: This work has expanded the sample to include 150 families meeting the strictest diagnostic definition of verified PD, and performs analyses using only those pedigrees with the strongest family history of PD, which strongly suggests that variation in a gene on chromosome 2q36-37 contributes to PD susceptibility.
Journal ArticleDOI

Rasagiline improves quality of life in patients with early Parkinson's disease

Kevin M. Biglan, +88 more
- 01 May 2006 - 
TL;DR: Rasagiline improved QOL compared with placebo, and this QOL improvement appears to be accounted for primarily by the symptomatic benefit of rasagILine.